UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

Age
99 years or below
Gender
All
participants needed
25
Location
1
UPCC 07917: Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

Brief description of study

TBD

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: solid tumor, cancer
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 828778
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research